VTv Therapeutics PE Ratio 2014-2021 | VTVT

Current and historical p/e ratio for VTv Therapeutics (VTVT) from 2014 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. VTv Therapeutics PE ratio as of October 22, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

VTv Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 1.40 0.00
2021-06-30 2.28 $-0.10 0.00
2021-03-31 2.82 $-0.16 0.00
2020-12-31 1.86 $-0.19 0.00
2020-09-30 1.77 $-0.34 0.00
2020-06-30 2.25 $-0.44 0.00
2020-03-31 1.91 $-0.47 0.00
2019-12-31 1.70 $-0.62 0.00
2019-09-30 1.55 $-0.59 0.00
2019-06-30 1.43 $-0.52 0.00
2019-03-31 1.71 $-0.73 0.00
2018-12-31 2.65 $-0.77 0.00
2018-09-30 0.77 $-1.11 0.00
2018-06-30 1.54 $-1.43 0.00
2018-03-31 4.07 $-1.53 0.00
2017-12-31 6.01 $-1.67 0.00
2017-09-30 5.98 $-1.65 0.00
2017-06-30 4.97 $-1.68 0.00
2017-03-31 6.55 $-1.74 0.00
2016-12-31 4.83 $-1.72 0.00
2016-09-30 7.19 $-1.65 0.00
2016-06-30 5.80 $-1.73 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.117B $0.006B
vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76